Overview

To define the prevalence, duration and severity of propofol-associated euphoria in patients undergoing painless gastrointestinal endoscopy and to explore the independent influencing factors by means of a single-center, cross-sectional clinical research study

Eligibility

Inclusion Criteria:

• Proposed to perform painless GI endoscopy, and simple endoscopic maneuvers such as single small polyp clamping, performing HP examination, etc;
• Gender is not limited;
• 18 years old ≤ 80 years old;
• ASA classification: I-II;
• 18 kg/m2 <BMI <30 kg/m2;
• Informed consent, voluntary participation in the trial, and informed consent signed by the subjects themselves.

Exclusion Criteria:

• adjudicated respiratory management difficulties;
• History of substance abuse as well as drug use;
• Participation in a clinical trial of another drug or device within 3 months prior to the screening period
• Use of therapeutic drugs (e.g., benzodiazepines, opioid analgesics) by the subject within 3 months prior to the Screening Period for a variety of reasons (e.g., insomnia, pain, etc.) that may have an impact on the outcome of the trial, etc;
• Allergy or contraindication to the study drug or components thereof;
• Previous psychiatric or neurological disorders (e.g., schizophrenia, mania, bipolar disorder, psychosis, epilepsy, neuralgia, etc.) and a history of taking medications corresponding to the treatment of the corresponding psychiatric or neurological disorders (e.g., antidepressants, anxiolytics, convulsants, antiepileptic drugs, etc.);
• Pregnant women;
• Subjects with severe communication disorders due to severe hearing deterioration;
• Refusal to participate in this study;
• Those deemed unsuitable by the investigator.